Alkermes Inc. plc - ALKS STOCK NEWS

Alkermes plc (Nasdaq: ALKS) announced on April 25, 2023, that it received a Second Interim Award from an arbitral tribunal regarding its license agreements with Janssen Pharmaceutica N.V.. The award mandates Janssen to pay approximately $194 million in back royalties related to fiscal year 2022. Key points include:

• Royalty terms for INVEGA SUSTENNA end on Aug. 20, 2024.
• INVEGA TRINZA royalties last until May 2030.
• INVEGA HAFYERA royalties expire in May 2030.
• CABENUVA royalties extend until Dec. 31, 2036.

The tribunal instructed both parties to confer within 21 days about further proceedings. The Second Interim Award follows a previous interim ruling that prevented Janssen from selling certain products without paying royalties.

NORTHAMPTON, MA / ACCESSWIRE / April 24, 2023 / Katie Joyce, Vice President of Corporate Affairs at Alkermes, recently participated in a panel discussion at the Women in Bio (WIB) Management Track event. This event allowed attendees to connect with influential women leaders in the life sciences sector, providing insights into their career journeys and unique experiences. The panel highlighted the importance of women in leadership roles within the industry, showcasing the diverse paths taken by these executives. For more information about Women In Bio, visit their website.

Alkermes plc (Nasdaq:ALKS) announced the opening of applications for its Alkermes Inspiration Grants program on May 1, 2023. The program aims to distribute $500,000 in total grants to nonprofit organizations addressing addiction, serious mental illness, and cancer. This marks the seventh year of the program, which evaluates proposals focused on underrepresented populations dealing with challenges such as alcohol dependence, opioid dependence, and certain cancers. Submissions will be accepted until June 1, 2023, with grant recipients selected based on defined criteria. Alkermes emphasizes its commitment to empowering communities and supporting organizations that complement medical care.

Alkermes reiterates its commitment to addressing Alcohol Use Disorder (AUD) during National Minority Health Month and Alcohol Awareness Month. The press release highlights the disproportionate impact of AUD on certain communities, underscoring the company's dedication to support individuals affected by this disorder. The emphasis is placed on the need for awareness and support as part of their ongoing efforts to combat AUD and promote health equity.

The company aims to foster a broader understanding of AUD's implications and the importance of targeted approaches in healthcare. Further details can be accessed through Alkermes' multimedia storytelling available online.

On April 19, 2023, Alkermes plc (NASDAQ: ALKS) announced a conference call and webcast scheduled for April 26, 2023, at 8:00 a.m. ET to discuss its first quarter financial results. Interested parties can access the event through Alkermes' website, with a replay available two hours post-event. Alkermes focuses on developing innovative medications in neuroscience and oncology, with products targeting alcohol and opioid dependence, schizophrenia, and bipolar I disorder. The company has a global presence with facilities in Ireland and the U.S. Investors can expect insights into the company's financial performance and future outlook during the call.

Alkermes plc (Nasdaq: ALKS) announced the opening of its Alkermes Inspiration Grants program, starting from May 1, 2023. The program, now in its seventh year, will allocate up to $500,000 in grants to support nonprofit organizations addressing issues related to addiction, serious mental illness, and cancer. CEO Richard Pops emphasized the importance of empowering nonprofits tackling complex health challenges. The grants will focus on programs that assist populations affected by alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, melanoma, or ovarian cancer. Eligible U.S. 501(c)(3) nonprofits can submit applications until June 1, 2023. For more details and application guidelines, visit Alkermes Inspiration Grants.

Alkermes plc (Nasdaq: ALKS) has submitted a confidential draft Form 10 registration statement to the U.S. Securities and Exchange Commission, marking a significant step in its planned separation of the oncology business into a publicly traded entity, Oncology Co. This separation, expected to be completed in the second half of 2023, aims to unlock shareholder value by creating focused operational structures for each business. The Board of Directors approved the split to enhance the profitability of its neuroscience segment while the oncology branch will continue developing cancer therapies, including nemvaleukin alfa. Alkermes has retained Morgan Stanley and BofA Securities for financial advice regarding this initiative, emphasizing its commitment to advancing its strategic focus.

Alkermes has been recognized in Ragan Communications and PR Daily's 2023 list of Top Places to Work. This accolade highlights the company's commitment to creating a positive work environment and employee satisfaction.

The announcement underscores Alkermes' focus on workplace culture, which may enhance its reputation and attract talent. For those interested in joining the team, job opportunities are available on their careers page.

Alkermes plc (Nasdaq: ALKS) announced the publication of the ENLIGHTEN-Early study results for LYBALVI (olanzapine and samidorphan) in the Journal of Clinical Psychiatry. The phase 3 trial focused on body weight effects in young adults (ages 16-39) with schizophrenia or bipolar I disorder. LYBALVI demonstrated a statistically significant reduction in weight gain compared to olanzapine, with mean weight changes at Week 12 being 4.91% for LYBALVI versus 6.77% for olanzapine (p=0.012). The safety profile was consistent with prior studies. The findings contribute to the understanding of LYBALVI as a treatment option for patients early in their illness.